Czech Lymphoma Study Group
8
3
3
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 8 trials
100.0%
+13.5% vs industry average
25%
2 trials in Phase 3/4
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (8)
IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.
Role: collaborator
Master Framework For Relapse or Refractory Acute Myeloid Leukemia
Role: collaborator
Brentuximab Vedotin in Combination With CHEP in Patient With PTCL
Role: lead
Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL
Role: lead
Non-Hodgkin Lymphoma - Observational Epidemiological and Clinical Study (NiHiL)
Role: lead
Observational Study for Patients With Newly Diagnosed (MCL) Not Eligible for High-dose Therapy
Role: lead
CNS Prophylaxis in Diffuse Large B-cell Lymphoma
Role: lead
R-MegaCHOP-ESHAP-BEAM in Patients With High-Risk Aggressive B-Cell Lymphomas
Role: lead
All 8 trials loaded